The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Can In Silico Modeling Speed Development?
Although Unproven, Some Advocates Believe the Technology Can Save Both Time and Money
- The current approach to drug development has not served the industry well. Fewer drugs are being approved, even as R&D investments spiral upward. The long-accepted protocol of in vitro testing of compounds followed by in vivo animal studies appears to be less satisfactory than in the past at predicting ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.